We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 17 and set a price target of ...
Testing has shown reduced bioavailability due to impurities and fibril formation, rendering these products less effective ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback